Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients
Data de publicación
2013Título da revista
EUROPEAN JOURNAL OF CANCER
Tipo de contido
Publicación de congreso